{"id":"NCT00192023","sponsor":"Eli Lilly and Company","briefTitle":"An Italian Study of the Efficacy of Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Oppositional Defiant Disorder (ODD).","officialTitle":"An Italian Randomised, Double-blind Placebo Controlled Study of the Efficacy of Atomoxetine Hydrochloride in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10","primaryCompletion":"2006-08","completion":"2008-05","firstPosted":"2005-09-19","resultsPosted":"2010-01-18","lastUpdate":"2010-01-18"},"enrollment":139,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder","Oppositional Defiant Disorder"],"interventions":[{"type":"DRUG","name":"atomoxetine 0.5 mg/kg/day","otherNames":["LY139603","Strattera"]},{"type":"DRUG","name":"placebo","otherNames":[]},{"type":"DRUG","name":"atomoxetine 1.2 mg/kg/day","otherNames":["LY139603","Strattera"]},{"type":"DRUG","name":"atomoxetine 1.2-1.4 mg/kg/day","otherNames":["LY139603","Strattera"]}],"arms":[{"label":"Atomoxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study is a phase IIIb multicentre, randomised, placebo controlled, trial in paediatric patients with Attention-Deficit/Hyperactivity (ADHD) and Oppositional Defiant Disorder (ODD). The primary aim of the study is to evaluate the efficacy of atomoxetine in improving ADHD and ODD symptoms in patients non responders to a previous psychological intervention with parent support. Moreover, the potential role of atomoxetine in treating other psychiatric comorbid conditions associated with ADHD and ODD will be assessed.","primaryOutcome":{"measure":"Change From Baseline to 8 Week Endpoint in Swanson, Nolan and Pelham Questionnaire (SNAP-IV): Attention-Deficit/Hyperactivity Disorder (ADHD) Subscale","timeFrame":"Visit 8 (baseline) and Visit 14 (8 weeks)","effectByArm":[{"arm":"Atomoxetine","deltaMin":42.7,"sd":6.2},{"arm":"Placebo","deltaMin":41.5,"sd":6.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":12,"countries":["Italy"]},"refs":{"pmids":["25019647"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":107},"commonTop":["Anorexia","Headache","Somnolence","Vomiting","Nausea"]}}